ReviewTrends in biotechnology2015
Selection strategies for anticancer antibody discovery: searching off the beaten path.
Review in Trends in biotechnology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Bispecific Antibody Format and the Organization of Immunological Synapses in T Cell-Redirecting Strategies for Cancer Immunotherapy.Pharmaceutics · 2022Review
- Regulation mechanism of ferroptosis and its research progress in tumor immunotherapy.Frontiers in molecular biosciences · 2022Review
- Parallel evaluation of cell‑based phage display panning strategies: Optimized selection and depletion steps result in AML blast‑binding consensus antibodies.Molecular medicine reports · 2021Article
- Development of a bispecific immune engager using a recombinant malaria protein.Cell death & disease · 2021Article
- Antibody Identification for Antigen Detection in Formalin-Fixed Paraffin-Embedded Tissue Using Phage Display and Naïve Libraries.Antibodies (Basel, Switzerland) · 2021Review
- Ligand Engineering via Yeast Surface Display and Adherent Cell Panning.Methods in molecular biology (Clifton, N.J.) · 2020Article
- A novel tetravalent bispecific antibody targeting programmed death 1 and tyrosine-protein kinase Met for treatment of gastric cancer.Investigational new drugs · 2019Article
- Recent advances in targeted therapy of colorectal cancer: impacts of monoclonal antibodies nanoconjugates.BioImpacts : BI · 2019Article
- Bispecific light T-cell engagers for gene-based immunotherapy of epidermal growth factor receptor (EGFR)-positive malignancies.Cancer immunology, immunotherapy : CII · 2018Article
- Selection of phage-displayed accessible recombinant targeted antibodies (SPARTA): methodology and applications.JCI insight · 2018Article
- Rapid Construction of Antitumor T-cell Receptor Vectors from Frozen Tumors for Engineered T-cell Therapy.Cancer immunology research · 2018Article
- Engineering Platforms for T Cell Modulation.International review of cell and molecular biology · 2018Review
- Modular Construction of Large Non-Immune Human Antibody Phage-Display Libraries from Variable Heavy and Light Chain Gene Cassettes.Methods in molecular biology (Clifton, N.J.) · 2018Article
- Strategies for Selecting Membrane Protein-Specific Antibodies using Phage Display with Cell-Based Panning.Antibodies (Basel, Switzerland) · 2017Review
- A novel excision selection method for isolation of antibodies binding antigens expressed specifically by rare cells in tissue sections.Nucleic acids research · 2017Article
- Geometry and expression enhance enrichment of functional yeast-displayed ligands via cell panning.Biotechnology and bioengineering · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 3 countries.
Funding
Abstract
Antibody-based drugs represent one of the most successful and promising therapeutic approaches in oncology. Large combinatorial phage antibody libraries are available for the identification of therapeutic antibodies and various technologies exist for their further conversion into multivalent and multispecific formats optimized for the desired pharmacokinetics and the pathological context. However, there is no technology for antigen profiling of intact tumors to identify tumor markers targetable with antibodies. Such constraints have led to a relative paucity of tumor-associated antigens for antibody targeting in oncology. Here we review novel approaches aimed at the identification of antibody-targetable, accessible antigens in intact tumors. We hope that such advanced selection approaches will be useful in the development of next-generation antibody therapies for cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.